Ignite Creation Date:
2025-12-24 @ 11:29 PM
Ignite Modification Date:
2025-12-31 @ 3:55 AM
Study NCT ID:
NCT01778556
Status:
COMPLETED
Last Update Posted:
2019-11-13
First Post:
2013-01-26
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Short-term Effects of Leptin in People With Lipodystrophy
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D008060', 'term': 'Lipodystrophy'}, {'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D015228', 'term': 'Hypertriglyceridemia'}], 'ancestors': [{'id': 'D012875', 'term': 'Skin Diseases, Metabolic'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}, {'id': 'D052439', 'term': 'Lipid Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}, {'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D006949', 'term': 'Hyperlipidemias'}, {'id': 'D050171', 'term': 'Dyslipidemias'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C415771', 'term': 'metreleptin'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'brownrebecca@mail.nih.gov', 'phone': '301-594-0609', 'title': 'Dr. Rebecca Brown', 'organization': 'NIDDK'}, 'certainAgreement': {'piSponsorEmployee': True}}, 'adverseEventsModule': {'timeFrame': '6 months', 'eventGroups': [{'id': 'EG000', 'title': 'Intervention 1 (5 Days) : Leptin Naive', 'description': 'Studied for 5 days without taking metreleptin.\n\nMetreleptin: Recombinant analog of the human hormone, leptin', 'otherNumAtRisk': 15, 'deathsNumAtRisk': 15, 'otherNumAffected': 0, 'seriousNumAtRisk': 15, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'Intervention 2 (14 Days): Leptin Naive', 'description': 'Studied for 14 days while taking metreleptin after the intervention 1 (5 days) : Leptin Naive Metreleptin: Recombinant analog of the human hormone, leptin', 'otherNumAtRisk': 15, 'deathsNumAtRisk': 15, 'otherNumAffected': 2, 'seriousNumAtRisk': 15, 'deathsNumAffected': 0, 'seriousNumAffected': 1}, {'id': 'EG002', 'title': 'Long-term Follow-up (6 Months): Leptin Naive', 'description': 'Studied for 6 months while taking metreleptin after intervention 2 (14 days): Leptin Naive\n\nMetreleptin: Recombinant analog of the human hormone, leptin', 'otherNumAtRisk': 15, 'deathsNumAtRisk': 15, 'otherNumAffected': 4, 'seriousNumAtRisk': 15, 'deathsNumAffected': 0, 'seriousNumAffected': 2}, {'id': 'EG003', 'title': 'Intervention 1 ( 5 Days) : On-Leptin', 'description': 'Studied for 5 days while taking metreleptin\n\nMetreleptin: Recombinant analog of the human hormone, leptin', 'otherNumAtRisk': 8, 'deathsNumAtRisk': 8, 'otherNumAffected': 0, 'seriousNumAtRisk': 8, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG004', 'title': 'Intervention 1 ( 14 Days): On-Leptin', 'description': 'Studied for 14 days during metreleptin withdrawal after Intervention 1 ( 5 days) : On-Leptin\n\nMetreleptin: Recombinant analog of the human hormone, leptin', 'otherNumAtRisk': 8, 'deathsNumAtRisk': 8, 'otherNumAffected': 0, 'seriousNumAtRisk': 8, 'deathsNumAffected': 0, 'seriousNumAffected': 0}], 'otherEvents': [{'term': 'decreased appetite', 'stats': [{'groupId': 'EG000', 'numAtRisk': 15, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 15, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 15, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 8}, {'groupId': 'EG004', 'numAtRisk': 8}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT'}, {'term': 'weight loss', 'stats': [{'groupId': 'EG000', 'numAtRisk': 15, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 15, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 15, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 8}, {'groupId': 'EG004', 'numAtRisk': 8}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT'}, {'term': 'hair loss', 'stats': [{'groupId': 'EG000', 'numAtRisk': 15, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 15, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 15, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 8}, {'groupId': 'EG004', 'numAtRisk': 8}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT'}, {'term': 'hypoglycemia (in a subject treated with insulin)', 'stats': [{'groupId': 'EG000', 'numAtRisk': 15, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 15, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 15, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 8}, {'groupId': 'EG004', 'numAtRisk': 8}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT'}, {'term': 'injection site reaction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 15, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 15, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 15, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8}, {'groupId': 'EG004', 'numAtRisk': 8}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT'}, {'term': 'menorrhagia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 15, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 15, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 15, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8}, {'groupId': 'EG004', 'numAtRisk': 8}], 'organSystem': 'Endocrine disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT'}], 'seriousEvents': [{'term': 'abdominal pain of unknown etiology', 'notes': 'This adverse event was happened within 30 days window after the end of long-term follow-up.', 'stats': [{'groupId': 'EG000', 'numAtRisk': 15, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 15, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 15, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 8}, {'groupId': 'EG004', 'numAtRisk': 8}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT'}, {'term': 'angioedema secondary to angiotensin- converting enzyme inhibitor use', 'stats': [{'groupId': 'EG000', 'numAtRisk': 15, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 15, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 15, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 8}, {'groupId': 'EG004', 'numAtRisk': 8}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT'}, {'term': 'anemia secondary to menorrhagia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 15, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 15, 'numEvents': 4, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 15, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 8}, {'groupId': 'EG004', 'numAtRisk': 8}], 'organSystem': 'Endocrine disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT'}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Total Body Insulin Sensitivity', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Leptin Naive', 'description': 'Studied for 5 days without metreleptin, then 14 days while taking metreleptin\n\nMetreleptin: Recombinant analog of the human hormone, leptin'}, {'id': 'OG001', 'title': 'On-leptin', 'description': 'Studied for 5 days while taking metreleptin, then 14 days during metreleptin withdrawal\n\nMetreleptin: Recombinant analog of the human hormone, leptin'}], 'classes': [{'title': 'Intervention 1 (5 days)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '4.4', 'spread': '2.3', 'groupId': 'OG000'}, {'value': '10.9', 'spread': '4.1', 'groupId': 'OG001'}]}]}, {'title': 'Intervention 2 (14 days)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '5.8', 'spread': '2.2', 'groupId': 'OG000'}, {'value': '6.4', 'spread': '1.8', 'groupId': 'OG001'}]}]}, {'title': 'Long-term follow-up (6 months)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '8.0', 'spread': '4.0', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Intervention 1 (5 days), Intervention 2 (14 days), and Long-term follow-up (6 months)', 'description': 'Total body insulin sensitivity (measured as glucose disposal rate during a hyperinsulinemic, euglycemic clamp)', 'unitOfMeasure': 'mg/kg fat-free mass/min', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'One patient at Period 2 (14 days) in Leptin naive arm was withdrew due to protocol violation.'}, {'type': 'SECONDARY', 'title': 'Insulin-mediated Suppression of Hepatic Glucose Production', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Leptin Naive', 'description': 'Studied for 5 days without metreleptin, then 14 days while taking metreleptin\n\nMetreleptin: Recombinant analog of the human hormone, leptin'}, {'id': 'OG001', 'title': 'On-leptin', 'description': 'Studied for 5 days while taking metreleptin, then 14 days during metreleptin withdrawal\n\nMetreleptin: Recombinant analog of the human hormone, leptin'}], 'classes': [{'title': 'Intervention 1 (5 days)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '61.2', 'spread': '23.4', 'groupId': 'OG000'}, {'value': '77.1', 'spread': '42.7', 'groupId': 'OG001'}]}]}, {'title': 'Intervention 2 (14 days)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '75.2', 'spread': '33.1', 'groupId': 'OG000'}, {'value': '63.8', 'spread': '31.7', 'groupId': 'OG001'}]}]}, {'title': 'Long-term follow-up (6 months)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '85.6', 'spread': '17.9', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Intervention 1 (5 days), Intervention 2 (14 days), and Long-term follow-up (6 months)', 'description': 'Hepatic insulin sensitivity (measured as suppression of endogenous glucose production during a hyperinsulinemic, euglycemic clamp)', 'unitOfMeasure': 'percentage', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Measurements were not available.'}, {'type': 'SECONDARY', 'title': 'Endogenous Rate of Appearance of Palmitate', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Leptin Naive', 'description': 'Studied for 5 days without metreleptin, then 14 days while taking metreleptin\n\nMetreleptin: Recombinant analog of the human hormone, leptin'}, {'id': 'OG001', 'title': 'On-leptin', 'description': 'Studied for 5 days while taking metreleptin, then 14 days during metreleptin withdrawal\n\nMetreleptin: Recombinant analog of the human hormone, leptin'}], 'classes': [{'title': 'Intervention 1 (5 days)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '3.2', 'spread': '1.3', 'groupId': 'OG000'}, {'value': '1.4', 'spread': '0.7', 'groupId': 'OG001'}]}]}, {'title': 'Intervention 2 (14 days)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '2.8', 'spread': '1.0', 'groupId': 'OG000'}, {'value': '1.7', 'spread': '0.6', 'groupId': 'OG001'}]}]}, {'title': 'Long-term follow-up (6 months)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '2.2', 'spread': '0.7', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Intervention 1 (5 days), Intervention 2 (14 days), and Long-term follow-up (6 months)', 'description': 'Endogenous Rate of Appearance of Palmitate is measured in plasma.', 'unitOfMeasure': 'μmol/kg fat-free mass/min', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Measurements were not available.'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Leptin Naive', 'description': 'Studied for 5 days without metreleptin, then 14 days while taking metreleptin\n\nMetreleptin: Recombinant analog of the human hormone, leptin'}, {'id': 'FG001', 'title': 'On-leptin', 'description': 'Studied for 5 days while taking metreleptin, then 14 days during metreleptin withdrawal\n\nMetreleptin: Recombinant analog of the human hormone, leptin'}], 'periods': [{'title': 'Intervention 1 (5 Days)', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '15'}, {'groupId': 'FG001', 'numSubjects': '10'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '15'}, {'groupId': 'FG001', 'numSubjects': '8'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '2'}]}], 'dropWithdraws': [{'type': 'Protocol Violation', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}]}, {'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}]}]}, {'title': 'Intervention 2 (14 Days)', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '15'}, {'groupId': 'FG001', 'numSubjects': '8'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '14'}, {'groupId': 'FG001', 'numSubjects': '8'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}]}], 'dropWithdraws': [{'type': 'Protocol Violation', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}]}]}, {'title': 'Long-term Follow-up', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '15'}, {'comment': 'no long-term follow-up period in on-leptin arm', 'groupId': 'FG001', 'numSubjects': '0'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '14'}, {'comment': 'no long-term follow-up period in on-leptin arm', 'groupId': 'FG001', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}]}], 'dropWithdraws': [{'type': 'noncompliance with metreleptin', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'BG000'}, {'value': '8', 'groupId': 'BG001'}, {'value': '23', 'groupId': 'BG002'}]}], 'groups': [{'id': 'BG000', 'title': 'Leptin Naive', 'description': 'Studied for 5 days without metreleptin, then 14 days while taking metreleptin\n\nMetreleptin: Recombinant analog of the human hormone, leptin'}, {'id': 'BG001', 'title': 'On-leptin', 'description': 'Studied for 5 days while taking metreleptin, then 14 days during metreleptin withdrawal\n\nMetreleptin: Recombinant analog of the human hormone, leptin'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '32', 'spread': '17', 'groupId': 'BG000'}, {'value': '25', 'spread': '6', 'groupId': 'BG001'}, {'value': '28', 'spread': '14', 'groupId': 'BG002'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '12', 'groupId': 'BG000'}, {'value': '5', 'groupId': 'BG001'}, {'value': '17', 'groupId': 'BG002'}]}, {'title': 'Male', 'measurements': [{'value': '3', 'groupId': 'BG000'}, {'value': '3', 'groupId': 'BG001'}, {'value': '6', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race/Ethnicity, Customized', 'classes': [{'categories': [{'title': 'White', 'measurements': [{'value': '9', 'groupId': 'BG000'}, {'value': '4', 'groupId': 'BG001'}, {'value': '13', 'groupId': 'BG002'}]}, {'title': 'Hispanic', 'measurements': [{'value': '4', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '6', 'groupId': 'BG002'}]}, {'title': 'African American', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '2', 'groupId': 'BG002'}]}, {'title': 'Asian', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}]}, {'title': 'Other', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Type of lipodystrophy', 'classes': [{'categories': [{'title': 'Generalized', 'measurements': [{'value': '3', 'groupId': 'BG000'}, {'value': '8', 'groupId': 'BG001'}, {'value': '11', 'groupId': 'BG002'}]}, {'title': 'Partial', 'measurements': [{'value': '12', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '12', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Subtype of lipodystrophy', 'classes': [{'categories': [{'title': 'Congenital generalized lipodystrophy', 'measurements': [{'value': '3', 'groupId': 'BG000'}, {'value': '7', 'groupId': 'BG001'}, {'value': '10', 'groupId': 'BG002'}]}, {'title': 'Familial partial lipodystrophy', 'measurements': [{'value': '12', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '12', 'groupId': 'BG002'}]}, {'title': 'Acquired generalized lipodystrophy', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Endogenous leptin level', 'classes': [{'categories': [{'measurements': [{'value': '9.5', 'spread': '10.2', 'groupId': 'BG000'}, {'value': '1.2', 'spread': '0.5', 'groupId': 'BG001'}, {'value': '7.4', 'spread': '10.1', 'groupId': 'BG002'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'ng/dl', 'dispersionType': 'STANDARD_DEVIATION'}]}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2018-05-14', 'size': 838788, 'label': 'Study Protocol and Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'Prot_SAP_000.pdf', 'typeAbbrev': 'Prot_SAP', 'uploadDate': '2019-06-24T12:50', 'hasProtocol': True}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NON_RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'CROSSOVER'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 25}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2013-01-26'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2019-02-25', 'completionDateStruct': {'date': '2018-02-23', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2019-10-21', 'studyFirstSubmitDate': '2013-01-26', 'resultsFirstSubmitDate': '2019-06-24', 'studyFirstSubmitQcDate': '2013-01-26', 'lastUpdatePostDateStruct': {'date': '2019-11-13', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2019-10-21', 'studyFirstPostDateStruct': {'date': '2013-01-29', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2019-11-13', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2018-02-23', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Total Body Insulin Sensitivity', 'timeFrame': 'Intervention 1 (5 days), Intervention 2 (14 days), and Long-term follow-up (6 months)', 'description': 'Total body insulin sensitivity (measured as glucose disposal rate during a hyperinsulinemic, euglycemic clamp)'}], 'secondaryOutcomes': [{'measure': 'Insulin-mediated Suppression of Hepatic Glucose Production', 'timeFrame': 'Intervention 1 (5 days), Intervention 2 (14 days), and Long-term follow-up (6 months)', 'description': 'Hepatic insulin sensitivity (measured as suppression of endogenous glucose production during a hyperinsulinemic, euglycemic clamp)'}, {'measure': 'Endogenous Rate of Appearance of Palmitate', 'timeFrame': 'Intervention 1 (5 days), Intervention 2 (14 days), and Long-term follow-up (6 months)', 'description': 'Endogenous Rate of Appearance of Palmitate is measured in plasma.'}]}, 'oversightModule': {'isFdaRegulatedDrug': True}, 'conditionsModule': {'keywords': ['Lipodystrophy', 'Leptin', 'Energy Expenditure', 'Diabetes', 'Hypertriglyceridemia'], 'conditions': ['Lipodystrophy']}, 'referencesModule': {'references': [{'pmid': '9022071', 'type': 'BACKGROUND', 'citation': 'Ahima RS, Dushay J, Flier SN, Prabakaran D, Flier JS. Leptin accelerates the onset of puberty in normal female mice. J Clin Invest. 1997 Feb 1;99(3):391-5. doi: 10.1172/JCI119172.'}, {'pmid': '8717038', 'type': 'BACKGROUND', 'citation': 'Ahima RS, Prabakaran D, Mantzoros C, Qu D, Lowell B, Maratos-Flier E, Flier JS. Role of leptin in the neuroendocrine response to fasting. Nature. 1996 Jul 18;382(6588):250-2. doi: 10.1038/382250a0.'}, {'pmid': '8589726', 'type': 'BACKGROUND', 'citation': 'Chehab FF, Lim ME, Lu R. Correction of the sterility defect in homozygous obese female mice by treatment with the human recombinant leptin. Nat Genet. 1996 Mar;12(3):318-20. doi: 10.1038/ng0396-318.'}, {'pmid': '37515588', 'type': 'DERIVED', 'citation': 'Quaye E, Chacko S, Startzell M, Brown RJ. Leptin Decreases Gluconeogenesis and Gluconeogenic Substrate Availability in Patients With Lipodystrophy. J Clin Endocrinol Metab. 2023 Dec 21;109(1):e209-e215. doi: 10.1210/clinem/dgad445.'}, {'pmid': '34677608', 'type': 'DERIVED', 'citation': 'Meral R, Malandrino N, Walter M, Neidert AH, Muniyappa R, Oral EA, Brown RJ. Endogenous Leptin Concentrations Poorly Predict Metreleptin Response in Patients With Partial Lipodystrophy. J Clin Endocrinol Metab. 2022 Mar 24;107(4):e1739-e1751. doi: 10.1210/clinem/dgab760.'}, {'pmid': '34223895', 'type': 'DERIVED', 'citation': 'Nguyen ML, Sachdev V, Burklow TR, Li W, Startzell M, Auh S, Brown RJ. Leptin Attenuates Cardiac Hypertrophy in Patients With Generalized Lipodystrophy. J Clin Endocrinol Metab. 2021 Oct 21;106(11):e4327-e4339. doi: 10.1210/clinem/dgab499.'}, {'pmid': '33890058', 'type': 'DERIVED', 'citation': 'Grover A, Quaye E, Brychta RJ, Christensen J, Startzell MS, Meehan CA, Valencia A, Marshall B, Chen KY, Brown RJ. Leptin Decreases Energy Expenditure Despite Increased Thyroid Hormone in Patients With Lipodystrophy. J Clin Endocrinol Metab. 2021 Sep 27;106(10):e4163-e4178. doi: 10.1210/clinem/dgab269.'}, {'pmid': '32573497', 'type': 'DERIVED', 'citation': 'Baykal AP, Parks EJ, Shamburek R, Syed-Abdul MM, Chacko S, Cochran E, Startzell M, Gharib AM, Ouwerkerk R, Abd-Elmoniem KZ, Walter PJ, Walter M, Muniyappa R, Chung ST, Brown RJ. Leptin decreases de novo lipogenesis in patients with lipodystrophy. JCI Insight. 2020 Jul 23;5(14):e137180. doi: 10.1172/jci.insight.137180.'}, {'pmid': '32191645', 'type': 'DERIVED', 'citation': 'Sekizkardes H, Chung ST, Chacko S, Haymond MW, Startzell M, Walter M, Walter PJ, Lightbourne M, Brown RJ. Free fatty acid processing diverges in human pathologic insulin resistance conditions. J Clin Invest. 2020 Jul 1;130(7):3592-3602. doi: 10.1172/JCI135431.'}, {'pmid': '31194872', 'type': 'DERIVED', 'citation': 'Sekizkardes H, Cochran E, Malandrino N, Garg A, Brown RJ. Efficacy of Metreleptin Treatment in Familial Partial Lipodystrophy Due to PPARG vs LMNA Pathogenic Variants. J Clin Endocrinol Metab. 2019 Aug 1;104(8):3068-3076. doi: 10.1210/jc.2018-02787.'}, {'pmid': '29723161', 'type': 'DERIVED', 'citation': 'Brown RJ, Valencia A, Startzell M, Cochran E, Walter PJ, Garraffo HM, Cai H, Gharib AM, Ouwerkerk R, Courville AB, Bernstein S, Brychta RJ, Chen KY, Walter M, Auh S, Gorden P. Metreleptin-mediated improvements in insulin sensitivity are independent of food intake in humans with lipodystrophy. J Clin Invest. 2018 Aug 1;128(8):3504-3516. doi: 10.1172/JCI95476. Epub 2018 Jul 16.'}, {'pmid': '28324110', 'type': 'DERIVED', 'citation': 'Brown RJ, Meehan CA, Cochran E, Rother KI, Kleiner DE, Walter M, Gorden P. Effects of Metreleptin in Pediatric Patients With Lipodystrophy. J Clin Endocrinol Metab. 2017 May 1;102(5):1511-1519. doi: 10.1210/jc.2016-3628.'}], 'seeAlsoLinks': [{'url': 'https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2013-DK-0057.html', 'label': 'NIH Clinical Center Detailed Web Page'}]}, 'descriptionModule': {'briefSummary': 'Background:\n\n\\- Lipodystrophy is a condition where people do not have enough fat in the body. People with lipodystrophy can have problems such as diabetes or an enlarged liver. Researchers are looking at how leptin, a hormone produced by fat cells, can help people with these problems. Leptin helps control appetite and how the body stores food. Taking leptin can help people with lipodystrophy eat less food, which may help treat diabetes and other problems. To better understand how leptin works, researchers want to do an inpatient study on leptin treatment in people with lipodystrophy.\n\nObjectives:\n\n\\- To study how leptin treatment affects lipodystrophy.\n\nEligibility:\n\n\\- Individuals between 14 and 70 years of age who have lipodystrophy.\n\nDesign:\n\n* All participants will have a 19-day stay at the National Institutes of Health Clinical Center. One group of participants will have tests for 5 days before starting to take leptin. They will then take leptin for 2 weeks, and have more tests. The other group of participants will have tests for 5 days while taking leptin. They will then take stop taking leptin for 2 weeks, and have more tests, and then they will start taking leptin again.\n* Participants will have regular blood and urine tests during the visit. Some of the blood tests will look at insulin levels. Some will look at how the body metabolizes sugar and fat. Other tests will check hormone levels, especially of reproductive hormones.\n* During the visit, participants will spend 3 separate days in a metabolic chamber, a special room that measures how many calories the body uses. Urine samples will be collected during these stays.\n* Participants will also have several body imaging studies, including magnetic resonance imaging and a body composition scan.\n* Physical activity will be tested with an exercise bicycle and an electronic activity monitor.\n* Participants will be asked questions about hunger and comfort levels throughout the stay.', 'detailedDescription': 'Background\n\nLeptin is an adipocyte-derived hormone that can be thought of as a signal from adipose tissue to the rest of the body conveying information about long-term nutritional status. Patients with lipodystrophy have leptin deficiency secondary to lack of adipose tissue, and thus represent a natural model for studying the effects of leptin deficiency and replacement in humans. Leptin replacement in lipodystrophy ameliorates metabolic and endocrine abnormalities, including reducing food intake, improving insulin resistance and diabetes, reducing ectopic lipid, and normalizing reproduction. The reduction in energy intake induced by leptin replacement is likely responsible for part of the improvements observed in glucose and lipid metabolism. The clinical effects of leptin that are independent of changes in energy intake, and the mechanisms underlying these effects, have been poorly explored in humans.\n\nAim\n\nThe primary aim of this study is to determine the energy intake-independent effects of leptin on energy metabolism in lipodystrophic subjects. The major aspects of energy metabolism to be studied are:\n\n1. Lipid metabolism, including fasting lipids, lipolysis and fatty acid turnover, and ectopic lipid storage.\n2. Glucose metabolism, including fasting glucose, endogenous glucose production, and insulin sensitivity\n3. Energy expenditure, including total and resting energy expenditure, skeletal muscle work efficiency, and spontaneous physical activity\n\nIn addition, the effects of leptin on endocrine and autonomic function will be examined, including effects on the thyroid, gonadal, and adrenal axes, as well as blood pressure, body temperature, and heart rate variability.\n\nMethods\n\nThis is a non-randomized, parallel group study. Two groups of patients aged 14 to 70 years with lipodystrophy will be studied: leptin naive and leptin treated. Minors will only be included in the leptin naive arm. All subjects will be stabilized on a weight maintenance diet for 5 days (Period 1). After this, leptin will be withdrawn from leptin treated subjects, and leptin will be initiated in leptin naive subjects for a period of 14 days (Period 2). The same isocaloric diet will be continued throughout both Periods, permitting study of leptin s effects independent of energy intake.\n\nAll subjects will undergo metabolic testing on admission, at the end of Period 1, and throughout Period 2, to generate a detailed short-term time course of the effects of leptin initiation or withdrawal. At the end of Period 2, leptin will be continued in the leptin naive subjects, and restarted in the leptin treated subjects. Repeat metabolic testing will be performed 6-12 months after leptin initiation in the leptin-naive cohort to generate information on leptin s long-term effects.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT'], 'maximumAge': '70 Years', 'minimumAge': '14 Years', 'healthyVolunteers': False, 'eligibilityCriteria': '* INCLUSION CRITERIA:\n* Age 14-70 years (children under age 18 will only be enrolled in the leptin-naive arm of the study\n* Clinically-significant lipodystrophy as defined in protocol 02-DK-0022 (Long Term Efficacy of Leptin Replacement in the Treatment of Lipodystrophy). Relevant inclusion criteria for enrollment in protocol 02-DK-0022 are (summarized):\n\n * Lipodystrophy identified by the study physician during physical examination as an absence of fat outside the range of normal\n * Circulating leptin levels \\< 12.0 ng/mL in females and \\< 8.0 ng/mL in males\n * Presence of at least one of the following metabolic abnormalities:\n\n 1. Diabetes as defined by the 2007 American Diabetes Association criteria\n 2. Fasting insulin \\>30 microU/mL\n 3. Fasting hypertriglyceridemia \\>200 mg/dL\n* Co-enrolled in protocol 02-DK-0022 and either:\n\n * Leptin naive, with plans to initiate leptin treatment during the current study. For the purpose of this study, leptin naive will be defined as having received no exogenous leptin in the 4 months prior to study participation. Thus, subjects who previously received leptin therapy, discontinued, and wish to restart are eligible.\n\nOr\n\n--Leptin treated, meaning the subject has taken a stable dose of exogenous leptin for a minimum of 4 months (adults over age 18, only)\n\nEXCLUSION CRITERIA:\n\nIn leptin treated subjects only, the following exclusion criteria apply:\n\n* Poorly controlled diabetes at study entry (hemoglobin A1c greater than or equal to 9%)\n* Poorly controlled hypertriglyceridemia at study entry (serum triglycerides \\> 800 mg/dL)\n* Extreme hypertriglyceridemia prior to leptin (triglycerides greater than 2000 mg/dL at initiation of leptin treatment)\n* History of chronic or recurrent acute pancreatitis (\\> 1 episode), or a single episode of pancreatitis while receiving leptin treatment\n* Lipase greater than the upper limit of normal (491 units/L) at study entry\n\nIn all subjects (leptin treated and leptin naive), the following exclusion criteria apply:\n\n* Known HIV infection or HIV-associated lipodystrophy\n* History of diabetic ketoacidosis\n* Active inflammatory disease (e.g. dermatomyositis)\n* Change in diabetes or lipid-lowering medications within the past 6 weeks\n* Estimated glomerular filtration rate \\< 30 mL/minute\n* Current or recent (past 2 weeks) use of systemic glucocorticoids\n* Inadequately controlled hypothyroidism (TSH \\< 0.4 or \\>4 mcIU/L) or change in thyroid medication in the past 8 weeks.\n* Pregnancy or breast-feeding\n* Psychiatric disorder impeding competence or compliance\n* Any medical condition or medication that will increase risk to the subject (e.g. ischemic heart disease, decompensated liver disease) or that will interfere with interpretation of study data (e.g. Cushing s syndrome).'}, 'identificationModule': {'nctId': 'NCT01778556', 'briefTitle': 'Short-term Effects of Leptin in People With Lipodystrophy', 'organization': {'class': 'NIH', 'fullName': 'National Institutes of Health Clinical Center (CC)'}, 'officialTitle': 'Short Term Effects of Leptin Withdrawal or Initiation in Lipodystrophy Independent of Energy Intake', 'orgStudyIdInfo': {'id': '130057'}, 'secondaryIdInfos': [{'id': '13-DK-0057'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Leptin naive', 'description': 'Studied for 5 days without metreleptin, then 14 days while taking metreleptin', 'interventionNames': ['Biological: Metreleptin']}, {'type': 'EXPERIMENTAL', 'label': 'On-leptin', 'description': 'Studied for 5 days while taking metreleptin, then 14 days during metreleptin withdrawal', 'interventionNames': ['Biological: Metreleptin']}], 'interventions': [{'name': 'Metreleptin', 'type': 'BIOLOGICAL', 'description': 'Recombinant analog of the human hormone, leptin', 'armGroupLabels': ['Leptin naive', 'On-leptin']}]}, 'contactsLocationsModule': {'locations': [{'zip': '20892', 'city': 'Bethesda', 'state': 'Maryland', 'country': 'United States', 'facility': 'National Institutes of Health Clinical Center, 9000 Rockville Pike', 'geoPoint': {'lat': 38.98067, 'lon': -77.10026}}], 'overallOfficials': [{'name': 'Rebecca J Brown, M.D.', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)', 'class': 'NIH'}, 'responsibleParty': {'type': 'SPONSOR'}}}}